Teresa Salazar-Catron, MD
Hospitalist · Maryville, TNNPI 1588741680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $489 and has fallen 80.7% since, to $94 in 2025. Among hospitalist clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$369
- Pfizer$227
- GSK$204
- Sunovion Pharmaceuticals Inc.$123
- Novo Nordisk$116
- E.r. Squibb & Sons, L.L.C.$108
- plus $969 from 28 others
What the payments were for
- Food & beverage$2,117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $369 |
| Pfizer | 16 | $227 |
| GSK | 12 | $204 |
| Sunovion Pharmaceuticals Inc. | 8 | $123 |
| Novo Nordisk | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 7 | $108 |
| Corium, LLC | 5 | $90 |
| Astellas Pharma US Inc | 4 | $69 |
| Eisai Inc. | 3 | $63 |
| Kyowa Kirin, Inc. | 3 | $47 |
| UCB, Inc. | 2 | $46 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Merck | 3 | $43 |
| Organogenesis Inc. | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Avanir Pharmaceuticals, Inc. | 3 | $39 |
| AstraZeneca | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $35 |
| Scilex Pharmaceuticals Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| AbbVie | 2 | $28 |
| Boehringer Ingelheim | 2 | $28 |
| Bayer | 2 | $28 |
| Boston Scientific | 1 | $25 |
| Inogen, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| CMP Pharma, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
How this compares
$2,117 in reported general payments places this provider in the 90th percentile of 349 hospitalist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 2,041 | $435,833 |
| NuplazidPimavanserin Tartrate | 23 | $53,475 |
| XareltoRivaroxaban | 208 | $44,938 |
| JardianceEmpagliflozin | 184 | $38,762 |
| JanuviaSitagliptin Phosphate | 126 | $28,932 |
| GemtesaVibegron | 138 | $27,143 |
| LinzessLinaclotide | 40 | $23,492 |
| NuedextaDextromethorphan Hbr/Quinidine | 29 | $22,119 |
| OzempicSemaglutide | 19 | $19,445 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $18,950 |
| Potassium Chloride | 1,253 | $18,858 |
| Pantoprazole Sodium | 1,118 | $18,082 |
| MyrbetriqMirabegron | 119 | $17,977 |
| Atorvastatin Calcium | 2,253 | $17,153 |
| Levothyroxine Sodium | 1,901 | $15,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $227 | $435,8332,041 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $28 | $55,873250 claims |
| Acadia Pharmaceuticals IncNuplazid | $17 | $53,47523 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $204 | $50,323111 claims |
| Johnson & JohnsonXarelto | $17 | $44,938208 claims |
| AbbVieLinzess, Namzaric | $28 | $30,17864 claims |
| MerckJanuvia | $43 | $28,932126 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $27,143138 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $39 | $22,11929 claims |
| Novo NordiskOzempic | $116 | $19,44519 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $17,977119 claims |
| NovartisEntresto | $369 | $11,41640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 349 hospitalist providers in Tennessee.
Other hospitalist in Maryville
- Jennifer WinbiglerMaryville$3K
- Kimberly GoodemoteMaryville$1K
- Kevin DonovanMaryville$1K
- Nathaniel RunneMaryville$1K
- Gerald OnuohaNashville$37K
- Sunil KripalaniNashville$23K
- Ankur SethMemphis$13K
- Eugene ScobeyMemphis$6K
- Monico BanezJackson$6K
- Omar AlsharifKnoxville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.